{"classes":[{"categories":[{"measurements":[{"groupId":"OG011","spread":"3.59","value":"19.6"},{"groupId":"OG012","spread":"2.77","value":"19.6"},{"groupId":"OG013","spread":"3.84","value":"17.7"},{"groupId":"OG014","spread":"23.2","value":"58.8"},{"groupId":"OG015","spread":"20.4","value":"67.9"},{"groupId":"OG016","spread":"20","value":"76.2"},{"groupId":"OG017","spread":"22.1","value":"61.5"},{"groupId":"OG018","spread":"28","value":"85.1"},{"groupId":"OG019","spread":"11.3","value":"65"},{"groupId":"OG020","spread":"24.5","value":"87.6"},{"groupId":"OG021","spread":"26.8","value":"113"},{"groupId":"OG022","spread":"28.1","value":"116"},{"groupId":"OG023","spread":"23.1","value":"100"},{"groupId":"OG024","spread":"33.2","value":"115"},{"groupId":"OG025","spread":"17","value":"97.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"5"},{"groupId":"OG012","value":"5"},{"groupId":"OG013","value":"6"},{"groupId":"OG014","value":"5"},{"groupId":"OG015","value":"6"},{"groupId":"OG016","value":"14"},{"groupId":"OG017","value":"4"},{"groupId":"OG018","value":"11"},{"groupId":"OG019","value":"7"},{"groupId":"OG020","value":"4"},{"groupId":"OG021","value":"8"},{"groupId":"OG022","value":"5"},{"groupId":"OG023","value":"9"},{"groupId":"OG024","value":"5"},{"groupId":"OG025","value":"6"}],"units":"Participants"}],"title":"Cycle 1, ROW patients"},{"categories":[{"measurements":[{"groupId":"OG011","spread":"11.9","value":"30.4"},{"groupId":"OG012","spread":"8.4","value":"28.7"},{"groupId":"OG013","spread":"9.97","value":"29.7"},{"groupId":"OG014","spread":"28.9","value":"89.5"},{"groupId":"OG015","spread":"20.1","value":"168"},{"groupId":"OG016","spread":"34.4","value":"97.5"},{"groupId":"OG017","spread":"25.1","value":"80"},{"groupId":"OG018","spread":"35.6","value":"123"},{"groupId":"OG019","spread":"51.2","value":"90.8"},{"groupId":"OG020","value":"142"},{"groupId":"OG021","spread":"56.7","value":"134"},{"groupId":"OG022","spread":"9.9","value":"167"},{"groupId":"OG023","spread":"58.2","value":"141"},{"groupId":"OG024","spread":"29.8","value":"147"},{"groupId":"OG025","spread":"27.2","value":"126"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"3"},{"groupId":"OG012","value":"4"},{"groupId":"OG013","value":"2"},{"groupId":"OG014","value":"3"},{"groupId":"OG015","value":"3"},{"groupId":"OG016","value":"8"},{"groupId":"OG017","value":"3"},{"groupId":"OG018","value":"7"},{"groupId":"OG019","value":"2"},{"groupId":"OG020","value":"1"},{"groupId":"OG021","value":"3"},{"groupId":"OG022","value":"2"},{"groupId":"OG023","value":"5"},{"groupId":"OG024","value":"5"},{"groupId":"OG025","value":"3"}],"units":"Participants"}],"title":"Cycle 3, ROW patients"}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"6"},{"groupId":"OG012","value":"6"},{"groupId":"OG013","value":"6"},{"groupId":"OG014","value":"5"},{"groupId":"OG015","value":"6"},{"groupId":"OG016","value":"20"},{"groupId":"OG017","value":"5"},{"groupId":"OG018","value":"11"},{"groupId":"OG019","value":"7"},{"groupId":"OG020","value":"4"},{"groupId":"OG021","value":"10"},{"groupId":"OG022","value":"6"},{"groupId":"OG023","value":"11"},{"groupId":"OG024","value":"6"},{"groupId":"OG025","value":"6"}],"units":"Participants"}],"description":"Pharmacokinetic (PK) parameters were calculated based on PDR001 serum concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed serum concentration following a dose.\n\nJapanese patients were not treated with PDR001 and therefore the PK parameters of this study drug are not applicable.","dispersionType":"Standard Deviation","groups":[{"description":"Single-agent LAG525 1 mg/kg Q2W","id":"OG000","title":"Phase 1: LAG525 1 mg/kg Q2W"},{"description":"Single-agent LAG525 3 mg/kg Q2W","id":"OG001","title":"Phase 1: LAG525 3 mg/kg Q2W"},{"description":"Single-agent LAG525 5 mg/kg Q2W","id":"OG002","title":"Phase 1: LAG525 5 mg/kg Q2W"},{"description":"Single-agent LAG525 10 mg/kg Q2W","id":"OG003","title":"Phase 1: LAG525 10 mg/kg Q2W"},{"description":"Single-agent LAG525 15 mg/kg Q2W","id":"OG004","title":"Phase 1: LAG525 15 mg/kg Q2W"},{"description":"Single-agent LAG525 240 mg Q2W","id":"OG005","title":"Phase 1: LAG525 240 mg Q2W"},{"description":"Single-agent LAG525 400 mg Q2W","id":"OG006","title":"Phase 1: LAG525 400 mg Q2W"},{"description":"Single-agent LAG525 3 mg/kg Q4W","id":"OG007","title":"Phase 1: LAG525 3 mg/kg Q4W"},{"description":"Single-agent LAG525 5 mg/kg Q4W","id":"OG008","title":"Phase 1: LAG525 5 mg/kg Q4W"},{"description":"Single-agent LAG525 10 mg/kg Q4W","id":"OG009","title":"Phase 1: LAG525 10 mg/kg Q4W"},{"description":"Single-agent LAG525 400 mg Q4W","id":"OG010","title":"Phase 1: LAG525 400 mg Q4W"},{"description":"Combination LAG525 0.3 mg/kg + PDR001 1 mg/kg (Q2W/Q2W)","id":"OG011","title":"Phase 1: LAG525 0.3 mg/kg Q2W + PDR001 1 mg/kg Q2W"},{"description":"Combination LAG525 1 mg/kg + PDR001 1 mg/kg (Q2W/Q2W)","id":"OG012","title":"Phase 1: LAG525 1 mg/kg Q2W + PDR001 1 mg/kg Q2W"},{"description":"Combination LAG525 80 mg + PDR001 80 mg (Q2W/Q2W)","id":"OG013","title":"Phase 1: LAG525 80 mg Q2W + PDR001 80 mg Q2W"},{"description":"Combination LAG525 80 mg + PDR001 240 mg (Q2W/Q2W)","id":"OG014","title":"Phase 1: LAG525 80 mg Q2W + PDR001 240 mg Q2W"},{"description":"Combination LAG525 240 mg + PDR001 240 mg (Q2W/Q2W)","id":"OG015","title":"Phase 1: LAG525 240 mg Q2W + PDR001 240 mg Q2W"},{"description":"Combination LAG525 240 mg + PDR001 300 mg (Q3W/Q3W)","id":"OG016","title":"Phase 1: LAG525 240 mg Q3W + PDR001 300 mg Q3W"},{"description":"Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W)","id":"OG017","title":"Phase 1: LAG525 400 mg Q3W + PDR001 300 mg Q3W"},{"description":"Combination LAG525 600 mg + PDR001 300 mg (Q3W/Q3W)","id":"OG018","title":"Phase 1: LAG525 600 mg Q3W + PDR001 300 mg Q3W"},{"description":"Combination LAG525 80 mg + PDR001 240 mg (Q4W/Q4W)","id":"OG019","title":"Phase 1: LAG525 80 mg Q4W + PDR001 240 mg Q4W"},{"description":"Combination LAG525 400 mg + PDR001 400 mg (Q4W/Q4W)","id":"OG020","title":"Phase 1: LAG525 400 mg Q4W + PDR001 400 mg Q4W"},{"description":"Combination LAG525 800 mg + PDR001 400 mg (Q4W/Q4W)","id":"OG021","title":"Phase 1: LAG525 800 mg Q4W + PDR001 400 mg Q4W"},{"description":"Combination LAG525 1000 mg + PDR001 400 mg (Q4W/Q4W)","id":"OG022","title":"Phase 1: LAG525 1000 mg Q4W + PDR001 400 mg Q4W"},{"description":"Combination LAG525 80 mg + PDR001 400 mg (Q2W/Q4W)","id":"OG023","title":"Phase 1: LAG525 80 mg Q2W + PDR001 400 mg Q4W"},{"description":"Combination LAG525 240 mg + PDR001 400 mg (Q2W/Q4W)","id":"OG024","title":"Phase 1: LAG525 240 mg Q2W + PDR001 400 mg Q4W"},{"description":"Combination LAG525 300 mg + PDR001 400 mg (Q2W/Q4W)","id":"OG025","title":"Phase 1: LAG525 300 mg Q2W + PDR001 400 mg Q4W"}],"paramType":"MEAN","populationDescription":"All patients in phase 1 who received at least one full or partial dose of PDR001 and who had at least one serum sample providing evaluable PK data.","reportingStatus":"POSTED","timeFrame":"pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 14 days (Q2W), 21 days (Q3W) and 28 days (Q4W).","title":"Phase 1: Maximum Observed Serum Concentration (Cmax) of PDR001","type":"SECONDARY","unitOfMeasure":"ug/mL"}